Responding to the rofecoxib withdrawal crisis: A new model for notifying patients at risk and their health care providers

被引:16
作者
Jain, A [1 ]
Atreja, A [1 ]
Harris, M [1 ]
Lehmann, M [1 ]
Burns, J [1 ]
Young, J [1 ]
机构
[1] Cleveland Clin Fdn, Cleveland, OH 44195 USA
关键词
D O I
10.7326/0003-4819-142-3-200502010-00008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: We decided to inform our patients of the withdrawal of rofecoxib, one of the largest drug withdrawals in United States history, and instruct them to contact their providers for guidance. Objective: To identify and inform patients and providers affected by the rofecoxib withdrawal. Design: Descriptive observational study. Setting: Tertiary care center with an electronic medical record (EMR) system. Patients: Patients with an active rofecoxib prescription within the EMR. Intervention: Existing information technology and traditional communication resources were used to automate the identifying and notifying of patients and providers and to deactivate rofecoxib prescriptions in the EMR. Measurements: characteristics of patients receiving rofecoxib at our institution, details of their prescription and provider, number of EMR alerts, and medication discontinuations. Results: The 11699 patients with a rofecoxib prescription in our practice were sent notifications within 24 hours of the withdrawal. Limitations: we did not directly measure the effect of our notification on patients or providers. Conclusions: information technology enabled our institution to rapidly identify and notify individual patients and their providers about an important drug withdrawal. The methods modeled a feasible way for health care organizations with EMRs to participate in notification processes that may be applicable in a variety of situations.
引用
收藏
页码:182 / 186
页数:5
相关论文
共 31 条
[1]   Effect of computerized physician order entry and a team intervention on prevention of serious medication errors [J].
Bates, DW ;
Leape, LL ;
Cullen, DJ ;
Laird, N ;
Petersen, LA ;
Teich, JM ;
Burdick, E ;
Hickey, M ;
Kleefield, S ;
Shea, B ;
Vander Vliet, M ;
Seger, DL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (15) :1311-1316
[2]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[3]  
*CAMH, 2004, OFF HDB CAMH
[4]   Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication [J].
Delorio, NM .
JOURNAL OF EMERGENCY MEDICINE, 2004, 26 (03) :305-307
[5]  
DICK S, 1997, COMPUTER BASED PATIE
[6]  
Folz-Murphy N, 1998, J AM MED INFORM ASSN, P260
[7]  
Foster Erica, 2003, J AHIMA, V74, P34
[8]   The safety of newly approved medicines - Do recent market removals mean there is a problem? [J].
Friedman, MA ;
Woodcock, J ;
Lumpkin, MM ;
Shuren, JE ;
Hass, AE ;
Thompson, LJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (18) :1728-1734
[9]  
Greene H L, 2000, Health News, V6, P4
[10]  
Harris C Martin, 2003, J Healthc Inf Manag, V17, P37